Regulation of the Galphaq Signaling Pathway by Regulators of G Protein Signaling Proteins, G Protein-Coupled Receptor Kinase 2, and Small Molecule Inhibitors.
Thal, David M.
2010
Abstract
Transmembrane signaling through G<sub>alpha</sub><sub>q</sub>-coupled receptors is linked to physiological processes such as cardiovascular development and smooth muscle function. Crystallographic studies have shown that G<sub> alpha</sub><sub>q</sub> forms an effector like interaction with G protein-coupled receptor kinase 2 (GRK2) in a manner that does not appear to sterically overlap with the binding site for regulators of G protein signaling (RGS) proteins. We confirm the formation of higher order RGS-G<sub>alpha</sub><sub>q</sub>-effector complexes using a flow cytometry protein interaction assay (FCPIA). Our data further supports the notion that GRK2 is a <italic>bona fide</italic> effector of G<sub>alpha</sub><sub>q</sub>. Small molecule inhibitors that could specifically inhibit the binding of G<sub>alpha</sub><sub>q</sub> to GRK2 would serve as powerful pharmacological tools that could be used to better understand the full significance of this interaction. We developed a high-throughput screening assay using FCPIA to identify small molecule inhibitors of the G<sub> alpha</sub><sub>q</sub>-GRK2 interaction. While our initial screening efforts failed to yield any discernable lead compounds, modifications of our assay could be used to screen additional chemical libraries that are better designed towards inhibiting protein-protein interactions. The canonical role of GRK2 is to phosphorylate the cytoplasmic tails/loops of activated G protein-coupled receptors (GPCRs). Phosphorylated receptors can then be uncoupled from G proteins, thereby desensitizing the signaling pathway. Since the discovery of a linkage between the over-expression of GRK2 and heart failure, GRK2 has become a pharmaceutical target for the treatment of heart disease. Takeda Pharmaceuticals have discovered a class of selective GRK2 inhibitors. We have solved the crystal structures of two of these compounds bound to GRK2-Gbetagamma. Our crystal structures reveal that these compounds bind to an inactive kinase conformation, in a manner similar to the cancer drug imatinib. Recently, an RNA aptamer has been discovered that is also capable of selectively inhibiting GRK2. Crystallographic data indicates that the aptamer stabilizes an inactive conformation similar to that recognized by the Takeda compounds. We have developed an aptamer displacement assay using FCPIA that is currently in use to screen for small molecule inhibitors that bind to this inactive kinase conformation.Subjects
G-protein Coupled Receptors Galphaq Kinase Pathway Protein-protein Structure Proteins Receptor Regulation Regulators Signaling Small Molecule Inhibitors
Types
Thesis
Metadata
Show full item recordCollections
Showing items related by title, author, creator and subject.
-
Detlefsen, David James (1990)
-
Katira, P.; Agarwal, A.; Fischer, T.; Chen, Hsien -Yeh.; Jiang, Xuwei; Lahann, Joerg (WILEY-VCH Verlag, 2007-10-19)
-
Scott, Jamie K.; Huang, Shan‐fu; Gangadhar, Beechanahalli P.; Samoriski, Gary M.; Clapp, Peter; Gross, Robert A.; Taussig, Ronald; Smrcka, Alan V. (John Wiley & Sons, Ltd, 2001-02-15)
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.